These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 11004820

  • 1. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y, Oyasu K, Wakamatsu T, Sumitomo Y, Kiyota K, Inokuchi H, Kawai K.
    Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
    [Abstract] [Full Text] [Related]

  • 2. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA, Kuppermann M, Richter JE.
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [Abstract] [Full Text] [Related]

  • 3. [Comparison between histamine H2-blocker and proton pump inhibitor on the effects of initial treatment in reflux esophagitis].
    Harasawa S.
    Nihon Rinsho; 2000 Sep; 58(9):1847-52. PubMed ID: 11004814
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
    Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G.
    Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
    [Abstract] [Full Text] [Related]

  • 7. [Cost-effectiveness analysis for the treatment of non-erosive reflux disease].
    Habu Y, Fukui Y, Maruno T, Hisatsune H, Kawai K.
    Nihon Rinsho; 2007 May; 65(5):951-5. PubMed ID: 17511239
    [Abstract] [Full Text] [Related]

  • 8. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
    Feldman M, Harford WV, Fisher RS, Sampliner RE, Murray SB, Greski-Rose PA, Jennings DE.
    Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
    [Abstract] [Full Text] [Related]

  • 9. PPIs vs H2RAs for erosive reflux esophagitis.
    King VJ.
    J Fam Pract; 1998 Mar; 46(3):199-200. PubMed ID: 9519012
    [No Abstract] [Full Text] [Related]

  • 10. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ, Hunt RH.
    Yale J Biol Med; 1999 Mar; 72(2-3):181-94. PubMed ID: 10780580
    [Abstract] [Full Text] [Related]

  • 11. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Robinson M, McFarland M, Sabesin S, Lehman GA, Castell D.
    Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
    [Abstract] [Full Text] [Related]

  • 12. [Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)].
    Endo M, Sugihara K.
    Nihon Rinsho; 2000 Sep; 58(9):1865-70. PubMed ID: 11004817
    [Abstract] [Full Text] [Related]

  • 13. [H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
    Bardou M.
    Rev Prat; 2001 Apr 15; 51(7):789-95. PubMed ID: 11387678
    [No Abstract] [Full Text] [Related]

  • 14. The medical management of reflux esophagitis. Role of antacids and acid inhibition.
    Sontag SJ.
    Gastroenterol Clin North Am; 1990 Sep 15; 19(3):683-712. PubMed ID: 1977703
    [Abstract] [Full Text] [Related]

  • 15. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM, Gerrity MS, Anderson T.
    Eff Clin Pract; 2001 Sep 15; 4(6):263-70. PubMed ID: 11769299
    [Abstract] [Full Text] [Related]

  • 16. [Recent topics in the medical treatment of reflux esophagitis].
    Hiraishi H, Shimada T, Terano A.
    Nihon Geka Gakkai Zasshi; 1997 Nov 15; 98(11):942-6. PubMed ID: 9488979
    [Abstract] [Full Text] [Related]

  • 17. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
    Festen HP, Schenk E, Tan G, Snel P, Nelis F.
    Am J Gastroenterol; 1999 Apr 15; 94(4):931-6. PubMed ID: 10201459
    [Abstract] [Full Text] [Related]

  • 18. Proton pump inhibitors: cost-effective agents for management of reflux-induced esophagitis.
    Gregor JC.
    Am J Manag Care; 2000 Aug 15; 6(8):934-5. PubMed ID: 11186505
    [No Abstract] [Full Text] [Related]

  • 19. Long-term management of gastroesophageal reflux disease and its complications.
    Richter JE.
    Am J Gastroenterol; 1997 Apr 15; 92(4 Suppl):30S-34S; discussion 34S-35S. PubMed ID: 9127624
    [Abstract] [Full Text] [Related]

  • 20. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
    Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Haber M.
    Am J Gastroenterol; 1996 Sep 15; 91(9):1758-65. PubMed ID: 8792694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.